I need to read the manuscript in detail. The important point is whether a clinically relevant effect can be seen. All drug compounds that advance from hit to lead show in vitro and cellular activities on relevant targets. Efficacy in disease models actually proves it can improve a condition in vivo (which cannot be done with Ampion) and leads to possible clinical trials.
So, they would need to prove that a clinically relevant effect could be seen with an approved dosage. Ampion showed cartilage growth in situ, but there was no evidence of it from STRUT. Still, there is some value with non-clinical MOA studies.
"ENGLEWOOD, Colo., May 3, 2016 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) announced today the acceptance of three new publications in peer-reviewed scientific forums that report mechanisms of action (MOA) of Ampion™."
Peer-reviewed scientific forums, not journals, is misrepresentation of the peer reviewed journals standard.
"Peer Review: Publication’s Gold Standard
...Scientific journals catalog the contributions, thoughts, and opinions of researchers, investigators, and experts in the field. Authors consider the reputation and quality of a journal prior to submitting a manuscript for consideration.
...The goal of peer review is to determine if an article should or should not be published and to improve the article before publication (Neale & Bowman, 2006). It is a process that entails filtering out manuscripts that are misleading, irrelevant, inaccurate, or that contain potentially harmful content (Kumar, 2009)."
Two posters in the halls at a convention for a couple of days is playing with the term "publication".
AAST Publishes the Journal of Trauma and Acute Care Surgery. AMPE's efforts were either not submitted or were rejected for publication is the Journal. See instructions for Abstract submission at the conventions website.
You gotta wonder what's in it for a couple of slick willies trying to slip some bait and switch past their investors.
It's good to see them doing some publications and taking part in industry events. The below excerpt is interesting. It looks like a heads up to something very cool coming soon. I suspect this is all part of the 'valuation' game they are in.
Dr. David Bar-Or, Ampio's Chief Science Officer, noted, "This manuscript reports Ampion™ up-regulates an important prostaglandin molecule (15d-PGJ2) associated with healing and resolution of inflammation in peripheral blood monocytes. These three publications in peer reviewed scientific forums further validate the scientific rationale for the use of the low molecular weight fraction of human serum albumin (Ampion™) in treating inflammatory conditions such as osteoarthritis. Several other scientific publications are in progress."
The new publications appear to back up an anti-inflammatory MOA of Ampion, at least in cell-culture. There still isn't any publication on possible healing in human OAK (STRUT) but they did state more in progress. This MOA has a longer term advantage over immediate pain relief MOAs, even though they can be stronger effects.
REGN fasinumab reported Phase 2/3 for moderate-to-severe osteoarthritis of the hip or knee
10-point (NRS) WOMAC, baseline = 6.3 4 arms (3 dose, 1 placebo), N=421
4 subcutaneous injections (Wk 0-Wk12) Endpoint at Wk 16
All doses (1,3,6,9mg) led to ca. -3.3 vs placebo -2.3 with excellent-to-modest p-values (0.0001-0.03)
So, 52% pain reduction vs 37% for placebo. Not all that impressive considering it was 4xMI and the endpoint was only 4 wks after the last injection. Fasinumab has had serious SE in the past. It is subQ vs IA injection, but Ampion is a much safer product based on available data.
At the moment getting through the $4.23-$4.25 level is proving to be near term resistance. Currently it looks like a possible double top. Keep it mind it went up nearly $2 in the month of April. While everyone waits for mid June early July it could do some back and filling in the next couple weeks.
it's $4.95 area - will provide more info later. But I look beyond that since the trial is driving higher volume, tech charts aren't as reliable as in "normal" trading.
Sentiment: Strong Buy
I've tried them all. Every newsletter in the business. Penny Stock 101 (org) is the only one that lives up to thge hype. They have the best NASDAQ, NYSE and OTCMarket alerts. Google them, sign up for their newsletter (it's no charge). You won't regret it!
"Hey shorty.What is the date of the not current information you refer to."
Have you no reading comprehension at all?
""The above was based on a search of YMB options."
YMB? Yahoo Message Board ? at the time I posted and even now: AMPE options calls Oct 21, 2016 as in -
5.00 AMPE161021C00005000 0.25 0.10 0.35 0.00 0.00%
There is a perpendicular column of words on a light blue background on the left side of the page after pulling up the YMB AMPE home screen. Two of the words in that column are 'Message Boards' another word, fourth line below the header "More on AMPE", is 'options'.
Click on it.
naples4sun • Apr 14, 2016 6:13 PM Flag
Welcome to Hotel California
Hey Shorts. You have checked in, but You can't get out. It's showtime!-
seems be the epitome of your posting drollery it is understandable you might not be aware that my handle and 'short on the scam known as AMPE' are synonymous.
In any case, once again , thank you for your redundancy.
"Market for $5 calls is .95 to $1.20"
Thanks for pointing out what I've already pointed out.
On a message board where many lack the stamina to read through the whole thread one cannot have too much assistance.
"The above was based on a search of YMB options. The information there is not current.
Using broker option premium and open interest information indicates that at present there is no pressing need to hedge in either direction."
"If that was true there wouldn't be Oct $5 c available for 35 cents.
The premiums on Puts suggests those selling them expect to have to cover."
The above was based on a search of YMB options. The information there is not current.
Using broker option premium and open interest information indicates that at present there is no pressing need to hedge in either direction.
A binary event is months away. The cautious trader would let the time value of premiums evaporate prior to opening a new position. With trial data not due for release until 3Q, 2016 reviewing options activity in July for the September and October contracts should reveal a clearer picture of market consensus regarding the direction of AMPE's share price.